Projects

ACCelerating Research for Early Development of Innovative Antibodies

Design improvement of homogeneous Antibody-Radionuclide-Drug Conjugates to reach promising and efficient crossfire treatments of cancersCoordination Dr Aurélie Maisonial-Besset, UMR 1240 IMoST INSERM Université Clermont Auvergne, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Clermont Ferrand (Tutelle : INSERM) Key words Antibody-radionuclide-drug conjugates (ARDC) Cancers Targeted radionuclide therapy Radiosensitization Bioconjugaison Key figures Budget : 1,65 M€ Duration : 4 years…

Multidisciplinary approach to stimulate the bioproduction and engineering of Gram+ bacteria’s Extracellular Vesicles (EVs) for therapeutic applications to treat inflammation

Bioengineering of next-generation skin substitutes for cutaneous regeneration

Improving the whole chain of large scale AAV bioproduction through disruptive technologies

Development of biotherapies based on the local delivery of therapeutic RNAs by hybrid functionalized extracellular vesicles (EVs) for musculoskeletal regeneration

Corneal bioimpression for advanced surgical reparation

Development of breakthrough technologies in gene editing

Hybrid iPSC bioartificial liver

Directional freezing of biologics in non-toxic conditions to enhance cell therapies’ activity and administration logisticsCoordination Francisco M. Fernandes (Laboratoire de Chimie de la Matière Condensée de Paris – LCMCP, UMR 7574) Sorbonne Université Key words Cryopreservation Directional freezing Cell therapy Non-toxic freezing media Control and observation of the freezing front Key figures Budget : 2,7…

Generation of iChondrocytes to regenerate articular cartilage

Genomic editing of stable universal pluripotent stem cells for allogeneic cell biotherapies

Chemical biology-enhanced monocyte engineering for innovative cell therapy against solid tumorsCoordination Alexandre Detappe, Equipe de Nanomédecine (Unité biothérapies innovantes, Inserm U1363 ) |Gustave Roussy Key words Monocyte cell therapy Switchable CAR Bioorthogonal chemistry Triple-negative breast cancer Theranostics Key figures Budget : 3 M€ Duration : 4 ans (2026 – 2030) Summary The challenge. Harnessing monocytes,…

Medication using specialized cell‐targeted lipid nanoparticle encapsulation in neuromuscular disorders

Bioengineered stem cell-derived retinal cells and tissue for cell therapy

Personalised phage therapy against gram-negative multidrug resIstant organisms

Innovative approaches for quality control to support the industrial deployment of future gene therapy products.

New Autonomously Replicating Non-Viral Vectors

New generation of mRNA-based vaccines

From engineering of iPS-derived mesenchymal stromal cell-derived extracellular vesicles to clinical translation